Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $302,325.17 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $302,325.17. Following the transaction, the chief operating officer directly owned 23,286 shares in the company, valued at approximately $2,239,880.34. The trade was a 11.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $222,312.06.

Mirum Pharmaceuticals Stock Up 2.1%

Shares of NASDAQ MIRM opened at $102.92 on Friday. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $103.81. The stock’s fifty day simple moving average is $79.65 and its two-hundred day simple moving average is $71.96. The stock has a market capitalization of $5.29 billion, a PE ratio of -119.67 and a beta of 0.48. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same period in the prior year, the business posted ($0.30) EPS. The firm’s quarterly revenue was up 47.1% on a year-over-year basis. As a group, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MCF Advisors LLC grew its stake in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth about $33,000. Comerica Bank lifted its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period. Quarry LP purchased a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $41,000. Finally, CWM LLC boosted its position in Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. JMP Securities set a $95.00 price target on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Stifel Nicolaus boosted their target price on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.92.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.